A pilot study was performed to obtain preliminary data regarding the need for targeted therapy of bacterial vaginosis (BV) when it accompanies clinically defined cervicitis. Specifically, women attending a sexually transmitted disease (STD) clinic with clinically defined BV and cervicitis were treated in the first phase of the study with doxycycline alone. In phase II, the patients received doxycycline and concomitant intravaginal metronidazole gel. All patients were reexamined 3-4 weeks after therapy. Persistence of BV occurred in 18/19 (95%) of women in phase I vs. 1/7 (14%) of women in phase II (P < 0.001). We concluded that, in women with coexistent clinically defined cervicitis and BV, the treatment of cervicitis does not result in a normalization of the vaginal flora. 
cervicitis is frequently observed by clinicians and is well documented in the literature. [1] [2] [3] [4] As many as 5 0% of the women attending sexually transmitted disease (STD) clinics with clinically defined cervicitis have BV. 3 Despite the frequent coexistence of these syndromes, no formal recommendations for the appropriate clinical management of patients with BV and cervicitis exist. In practice, many clinicians treat only the endocervical infections in such women. To begin to examine the management of BV in the setting of cervicitis and to determine the optimal therapy for patients with both syndromes, we conducted a pilot study of women with BV and cervicitis attending an inner-city STD clinic. Vaginal Gram's stains for the diagnosis of BV were interpreted in a blinded fashion using the scoring system ofNugent et al. 9 The quantitation of polymorphonuclear leukocytes on the endocervical smears was performed as described by Brunham et al. 7 The study was divided into 2 phases. During the first phase, the patients were treated for cervicitis with doxycycline, 100 12 However, the pathogenesis, including whether the disappearance of the lactobacilli is a primary cause or a result, is unknown. 13, 14 The syndrome of BV most commonly occurs among sexually active women and frequently coexists with other STDs. [1] [2] [3] [4] Up to 50% of women attending STD clinics with mucopurulent cervicitis also have BV. 3 In fact, the frequent coexistence of cervicitis and BV has led some investigators to question whether local factors associated with cervical inflammation may predispose to alterations in the vaginal flora. 'ls At a practical level, the most appropriate treatment of women with both syndromes is an important consideration. Despite the fact that the successful treatment of BV requires an antimicrobial agent with excellent activity against anaerobes, many practitioners feel that the treatment of cervicitis alone may result in a resolution of BV in this setting. Also of concern is that the potential gastrointestinal side effects associated with doxycycline and metronidazole might lead to poor patient compliance. The current availability of efficacious topical prepara- 11, 16 tions for treating BV obviates that concern, although their added expense is a factor to be considered.
SUBJECTS AND METHODS

Women
Our data suggest that treatment specific for both BV and cervicitis is necessary in order to promptly reestablish the normal vaginal ecology. Although the number of patients studied in this pilot study was 
